

• BRIEF REPORT •

Presence of Tissue Transglutaminase IgA Antibody as a Celiac Disease Marker in a Sample of Patients with Irritable Bowel Syndrome

Alberto L. Zamot, MD; Esther A. Torres, MD; Henry González, MD; Manuel A. Marcial, MD

Recent medical literature agrees that celiac disease (CD) is much more prevalent in western civilization than it was thought to be in the past. Given the potential complications and consequences of untreated CD, screening programs have been considered. Symptoms of celiac disease may resemble those of Irritable Bowel Syndrome. A group of patients with IBS was screened for CE using the Tissue Transglutaminase Antibody IgA serum test. A total of 18 patients were screened. All of our patients tested negative for TTG IgA. This finding may indicate that the prevalence of CD may be low in our population. Further population studies are needed to confirm our finding. [*PR Health Sci J* 2015;34:38-39]

Key words: Celiac Disease, Irritable Bowel Syndrome, Tissue transglutaminase IgA antibody, Puerto Rico

Celiac disease (CD), also known as gluten-sensitive enteropathy, is characterized by intolerance to gluten, rye, wheat, and barley. Diarrhea and malabsorption are 2 classic symptoms of the disease. These symptoms are caused by immune-mediated intestinal mucosal injury. Clinical manifestations of CD tend to differ by age group. Most of the literature agrees that CD is slightly more prevalent in women than in men. Its age distribution is bimodal, with the first peak in infancy and a second in the third to fourth decade of life. Extraintestinal manifestations are more common in adults than in children. These can be related to malabsorption but also may be independent of nutritional status. Malabsorption may cause iron deficiency, peripheral neuropathy, weakness, weight loss, night blindness, muscle cramps, bone demineralization, and bleeding disorders. Extra intestinal manifestations, independent of malabsorption, include dermatitis herpetiformis, neuropsychiatric disease, arthritis, myocarditis, liver dysfunction, lymphoma, glomerular disease, pulmonary hemosiderosis, migraines, depression, and infertility (1–3).

The perspective of CD in the United States has changed over the past decade. Previously, CD prevalence was estimated to be 1 case per 3000 to 6000 persons (1). The disease was thought to be exclusive to the European population, with a prevalence (in that population) of 1 case per 130 to 300 persons (2). However, more recent studies estimate that the prevalence of CD in the United States is closer to 1 case per 133 to 250 persons (1). Given this new epidemiological data, and the potentially severe consequences of untreated CD, the creation of a national screening program has been considered. The prevalence of CD in Puerto Rico has not been established, but studies in Latin America (Argentina and Brazil) identified the prevalence in

that region as being 1 case per 167 to 360 persons (4). This latter study indicates that the prevalence of CD in this Latin America population is very similar to the prevalence seen in the European population.

Aside from ethnic differences, there are certain patient groups that have an increased risk for CD. Patients with irritable bowel syndrome (IBS) very often have symptoms that are similar to those of patients with CD (5–6). Studies designed to address this finding have shown that patients with IBS have a higher prevalence of CD serologic markers than a control population (7). Other studies propose that CD-associated mucosal inflammation may have a sensitizing effect that predisposes certain individuals to IBS-type symptoms (8). These results often vary according to the study-subject sample being evaluated.

Some studies suggest that people with CD have modest increases in overall risk of malignancy, especially small intestinal lymphoma and GI carcinomas (3). It has also been well documented that CD has significant morbidity and a high risk for mortality because of its numerous complications. Therefore, an improvement in screening both to detect prevalence and to establish an early treatment will most likely improve patient survival and quality of life.

School of Medicine, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico

The tissue transglutaminase test was partially funded by Quest Diagnostic Laboratories, Inc. The authors have no conflicts of interest to disclose.

Address correspondence to: Esther A. Torres, MD, University of Puerto Rico Medical Sciences Campus, School of Medicine, GI Research Unit, Department of Medicine A-838, PO Box 365067, San Juan, PR 00936. Email: estheratorresmd@gmail.com

6. Nielsen-Bohlman L, Panzer AM, Kindig, DA, eds. *Health Literacy: A Prescription to End Confusion*. Committee on Health Literacy, Board on Neuroscience and Behavioral Health, Institute of Medicine. Washington, DC: The National Academies Press; 2004.
7. Van Servellen GV, Brown JS, Lombardi E, Herrera G. Health literacy in low-income Latino men and women receiving antiretroviral therapy in community-based treatment centers. *AIDS Patient Care STDS* 2003;17:283–298.
8. DeWalt DA, Pignone M, Malone R, Rawls C, Kosnar MC, George G, et al. Development and pilot testing of a disease management program for low literacy patients with heart failure. *Patient Educ Couns* 2004;55:78–86.
9. Wilson JF. The crucial link between literacy and health. *Ann Intern Med* 2003;139:875–878.
10. Wolf MS, Davis TC, Arozullah A, Penn R, Arnold C, Sugar M, Bennet CL. Relation between literacy and HIV treatment knowledge among patients on HAART regimens. *AIDS Care* 2005;17:863–873.
11. Wolf MS, Davis TC, Cross JT, Marin E, Green K, Bennett CL. Health literacy and patient knowledge in a Southern US HIV clinic. *Int J STD AIDS* 2004;15:747–752.
12. Rivero-Mendez M, Dawson Rose C, Solís-Baez S. A qualitative study of providers' perception of adherence of women living with HIV/AIDS in Puerto Rico. *Qual Rep* 2010;12:232–251.
13. Nurs JR, Parker RM, Baker DW. *TOFHLA: Test of functional health literacy in adults*. Hartford, MI: Peppercorn Books and Press, Inc.; 1995.
14. Rivero-Méndez M, Suárez E, Solís-Báez SS, Hernández G, Cordero W, Vázquez I, et al. Internal consistency of the Spanish health literacy test (TOFHLA-SPR) for Puerto Rico. *P R Health Sci J* 2010;29:49–53.
15. Artola GT. El Procedimiento cloze: una revisión general. *Rev Complut Educ* 1991;2:69–81.
16. Rivero-Mendez M, Portillo C, Solís SS, Wantland D, Holzemer, LW. Symptoms and quality of life of people living with HIV infection in Puerto Rico. *P R Health Sci J* 2009;28:54–59.
17. Chesney MA, Ickovics JR, Chambers, DB, Gifford, AL, Neidig J, Zwickl B, Wu AW. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). *AIDS Care* 2000;12:255–266.
18. Holzemer WL, Bakken S, Portillo CJ, Grimes R, Welch J, Wantland D, Mullan JT. Testing a nurse-tailored HIV medication adherence intervention. *Nurs Res* 2006;55:189–197.
19. Holzemer WL, Hudson A, Kersey KM, Hamilton MJ, Bakken S. The Revised Sign and Symptom Check-List for HIV (SSC-HIVrev). *J Assoc Nurses AIDS Care* 2001;12:60–70.
20. Stata [computer program]. Release 10. College Station, TX: Stata Corp LP; 2007.
21. Paasche-Orlow MK, Parker RM, Gazmararian JA, Nielsen-Bohlman LT, Rudd RR. The prevalence of limited health literacy. *J Gen Intern Med* 2004;20:175–184.
22. Shea JA, Beers BB, McDonald VJ, Quistberg DA, Ravenell KL, Asch DA. Assessing health literacy in African American and Caucasian adults: Disparities in rapid estimate of adult literacy in medicine (REALM) scores. *Fam Med* 2004;36:575–581.
23. Kalichman CS, Rompa D. Functional health literacy is associated with health status and health related knowledge in people living with HIV-AIDS. *J Acquir Immune Defic Syndr*, 2000 ;25:337–344.
24. Eller LS, Corless I, Bunch EH, Kempainen J, Holzemer WL, Nokes K, et al. Self-care strategies for depressive symptoms in people with HIV disease. *J Adv Nurs* 2005;51: 119–130.
25. Bhatia R, Hartman C, Kallen MA, Graham J, Giordano TP. Persons newly diagnosed with HIV infection are at high risk for depression and poor linkage to care: Results from the Steps Study. *AIDS Behav* 2011;15: 1161–1170.
26. Horberg MA, Silverberg MJ, Hurley LB, Towner WJ, Klein DB, Bersoff-Matcha S, et al. Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients. *J Acquir Immune Defic Syndr* 2008;47:384–390.
27. Roeloffs C, Sherbourne C, Unutzer J, Fink A, Tang L, Wells KB. Stigma and depression among primary care patients. *Gen Hosp Psychiatry* 2003;25:311–315.
28. Alegria M, Vera M, Freeman DH Jr, Robles R, Santos MC, Rivera CL. HIV infection, risk behaviors, and depressive symptoms among Puerto Rican sex workers. *Am J Public Health* 1994;84:2000–2002.
29. Leserman J. HIV disease progression: depression, stress, and possible mechanisms. *Biol Psychiatry* 2003;54:295–306.
30. Leserman J. Role of depression, stress, and trauma in HIV disease progression. *Psychosom Med* 2008;70:539–545.
31. Judd F, Komiti A, Chua P, Mijch A, Hoy J, Grech P, et al. Nature of depression in patients with HIV/AIDS. *Aust N Z J Psychiatry* 2005;39: 826–832.
32. Jovet-Toledo GG, Clatts MC, Rodriguez-Diaz CE, Goldsamt L, Vargas-Molina RL. Risk factors for suicide attempts in a clinic-based sample of people living with HIV in Puerto Rico. *AIDS Care* [serial online]. 2014;26:1032–1035. Available at: <http://dx.doi.org/10.1080/09540121.2014.894618>. Accessed March 14, 2014.
33. Lewis-Fernandez R, Das AK, Alfonso, C, Weissman MM, Olsson M. Depression in US Hispanics: diagnostic and management considerations in family practice. *J Am Board Fam Pract* 2005;18:282–296.
34. Wantland D J, Holzemer WL, Moezzi S, Willard SS, Arudo J, Kirksey K, et al. A randomized controlled trial testing the efficacy of an HIV/AIDS symptom management manual. *J Pain Symptom Manage* 2008;36: 235–246.
35. Eller LS, Rivero-Mendez M, Voss L, Chen WT, Chaiphalsarisidi P, lipinge S, et al. Depressive symptoms, self-esteem, HIV symptom management self-efficacy and self-compassion in people living with HIV. *AIDS Care* 2014;26:795–803.

Methods

Given the concern that CD prevalence is rising in western populations, our study group decided to address this issue. A study of patients visiting University of Puerto Rico School of Medicine gastroenterology clinics was conducted. The study investigators identified patients with symptoms suggestive of IBS. These patients were self-referred and were seeking medical attention regarding gastrointestinal complaints. Subjects fulfilling the Rome III criteria (9) for the diagnosis of IBS were invited to participate and, if agreeable, recruited by the investigators. Consent was obtained. Age and sex data were collected. Based on the Rome III criteria, each patient's IBS diagnosis was classified as being one of the following: diarrhea, constipation, mixed, or unsubtype IBS (9). After consent and IBS classification, a tissue transglutaminase IgA test was ordered. Patients were instructed to go to the selected laboratory for blood drawing. A total of 5mL of blood was drawn at Quest Diagnostics, in Hato Rey, PR. Tissue transglutaminase IgA antibody levels were identified by ELISA Immunoassay. Results were reported as negative when the levels were less than 5 U/mL, equivocal when they were from 5 to 8 U/mL, and positive when they were greater than 8 U/mL. This test has a sensitivity of 90% to 96% and a specificity of greater than 95% for identifying CD (10). Sblattero D et al. showed that this test is cost effective for the diagnosis of CD (11). Frequency distributions were computed to describe the demographic and clinical characteristics of the study group. The study was approved by the IRB of the University of Puerto Rico Medical Sciences Campus.

Discussion

A total of 32 patients were diagnosed with IBS. Seven patients were women and 25 were men. The mean age of the participants was 48.5 + 11.5 years. The predominant IBS type was IBS with constipation. The supporting symptoms for IBS were quantified. The majority of patients (31.3%) had 4 supporting symptoms (Table 1). Of our study population, 18 patients underwent serum sampling. Results were negative for tissue transglutaminase IgA antibodies for all 18 patients (100%).

This is the first report of serologic screening for tissue transglutaminase IgA antibodies in patients with IBS living in Puerto Rico. The results are limited by the study's small sample size and should not be interpreted as showing that there is an absence of CD in patients with IBS living in Puerto Rico. Even if we accept a prevalence of 1 case per 133 to 250 persons for the USA (1), or 1 case per 167 to 360 persons for Latin America (4), we would not statistically expect to find a case of CD with our limited testing sample of only 18. Given the potential risks to the patient of untreated CD and based on the current literature, which indicates that there may be a higher prevalence of CD in our hemisphere than has previously been thought to be the case, a larger prospective study should be done to definitively determine the prevalence of CD in Puerto Rico.

Table 1. Symptoms supportive of IBS diagnosis

Number of symptoms*	Number of patients	Percent (N = 32)
2	3	3/32 (9.4%)
3	6	6/32 (18.7%)
4	10	10/32 (31.3%)
5	8	8/32 (25.0%)
6	5	5/32 (16.6%)

*Symptoms include the following: abnormal stool frequency and/or fewer than 3 bowel movements per week; more than 3 bowel movements per week; lumpy/hard stools; loose, watery stool; straining on/urgent defecation.

Resumen

La literatura médica reciente está de acuerdo que la enfermedad celiaca (EC) es mucho más prevalente en el occidente de lo que se había pensado en un pasado. Dado a las posibles complicaciones y consecuencias de la EC no tratada, se han considerado programas de cernimiento. Se ha descrito que la EC puede presentar síntomas muy parecidos a los del síndrome del intestino irritable. Nuestro grupo tomó muestras a varios pacientes con enfermedad del intestino irritable y se le hizo cernimiento para EC utilizando la prueba de suero transglutaminasa IgA (TTG IgA). Un total de dieciocho pacientes fueron muestreados. Nuestro grupo de pacientes en su totalidad resultó ser negativo para TTG IgA. Este hallazgo pudiese indicar que la prevalencia de la EC es baja en nuestra población. Estudios poblacionales son necesarios para confirmar nuestro hallazgo.

References

- Leffler D, Saha S, Farrell RJ. Celiac Disease. *Am J Manag Care* 2003;9: 825–831.
- Nelsen DA Jr. Gluten-Sensitive Enteropathy (Celiac Disease): More Common Than You Think. *Am Fam Physician* 2002;66:2259–2266.
- Green PHR, Stavropoulos SN, Panagi SG, et al. Characteristics of adult celiac disease in the USA: results of a national survey. *Am J Gastroenterol* 2001;96:126–131.
- Araya QM. Improving the management of celiac disease: an urgent challenge [in Spanish]. *Rev Med Chil* 2006;134:361–364.
- Wahnschaffe U, Ulrich R, Riecken EO, Schulzke JD. Celiac Disease-like abnormalities in a subgroup of patients with irritable bowel syndrome. *Gastroenterology* 2001;121:1329–1338.
- Verdu E, Armstrong D, Murray J. Between Celiac Disease and Irritable Bowel Syndrome: The "No Man's Land" of Gluten Sensitivity. *Am J Gastroenterol* 2009;104:1587–1594.
- Sanders DS, Carter MJ, Hurlstone DP, et al. Association of adult celiac disease with irritable bowel syndrome: a case-control study in patients fulfilling ROME II criteria referred to secondary care. *Lancet* 2001;358:1504–1508.
- O'Leary C, Wieneke P, Buckley S, et al. Celiac disease and irritable bowel-type symptoms. *Am J Gastroenterol* 2002; 97:1463–1467.
- Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. In: Drossman DA, Corazziari E, Delvaux M, Spiller RC, Talley NJ, Thompson WG, Whitehead WE, eds. *Rome III: The Functional Gastrointestinal Disorders*, 3rd ed. McLean, VA: Degnon Associates, Inc.; 2006:1480–1491.
- Leffler DA, Schuppan D. Update on serologic testing in celiac disease. *Am J Gastroenterol* 2010;105:2520–2524.
- Sblattero D, Berti I, Trevisiol C, et al. Human recombinant tissue transglutaminase ELISA: an innovative diagnostic assay for celiac disease. *Am J Gastroenterol* 2000;95:1253–1257.

• CASE REPORT •

Sporadic Creutzfeldt-Jakob Disease in a Native Puerto Rican Patient

Esteban A. Del Pilar-Morales, MD*; Ignazio Cali, MSc†‡; Javier Chapas, MD§; Jorge Bertrán-Pasarell, MD*; Gianfranco Puoti, MD, PhD**; Pierluigi Gambetti, MD†; Ulises Nobo, MD††

The diagnosis of Creutzfeldt-Jakob disease (CJD) is often a challenge for most physicians given its extremely low incidence and different clinico-pathological presentations. We report the case of a 56-year old patient native to Puerto Rico suspected of sporadic Creutzfeldt-Jakob disease (sCJD). The symptoms at onset were notorious for bilateral cortical blindness followed by rapidly progressive cognitive decline, visual deficit, increased levels of CSF 14-3-3 and tau along with positive brain MRI and EEG, are highly indicative of CJD. The definite diagnosis was confirmed by the National Prion Disease Pathology Surveillance Center (NPDPSC), in Cleveland, Ohio, USA. Lack of genetic mutations in the prion protein (PrP) gene, widespread histopathological changes and the accumulation of scrapie PrP (PrP^{Sc}) in the brain confirmed the diagnosis of sCJD. The patient, admitted to our institution in 2011, represents the first detailed report of sCJD in a native Puerto Rican patient living in Puerto Rico. [*PR Health Sci J* 2015;34:40-43]

Key words: Creutzfeldt-Jakob Disease, Prion disease, Rapidly progressive dementia, CSF protein tau, CSF protein 14-3-3

Prion diseases are transmissible neurodegenerative disorders with different etiologies as they can be sporadic, genetic or acquired by infection (1,2). Sporadic Creutzfeldt-Jakob disease (sCJD) is the most common form of the sporadic human prion diseases. Despite this fact, sCJD remains a rare condition as it affects ~ 1 per 1 million cases per year worldwide (3). In sCJD and other human prion diseases, the codon 129 of the prion protein (PrP) gene, the site of a common methionine (M)/valine (V) polymorphism, and the two different types of the scrapie prion protein (PrP^{Sc}), are considered modifiers of the disease phenotype (1). Combinations of the codon 129 genotype (129MM, 129MV and 129VV) and PrP^{Sc} type (either type 1 or type 2) have been used to classify sCJD into five different subtypes⁴. The sCJDMM1 (e.g. 129MM and PrP^{Sc} type 1) is the most common subtype and accounts for 55-70% of all sporadic prion diseases (3,4).

Case Report

A 56 year-old woman with hypertension began experiencing headaches and episodes of spatial disorientation. Evaluated by her primary care physician, she underwent a head CT scan and general blood tests which resulted unremarkable. She was treated for tension headache. Within the following two months, visual difficulty was reported and the disorientation became more constant into the contest of a global rapidly progressive cognitive decline. Evaluation of cerebrospinal fluid (CSF) did

not reveal any abnormalities, whereas 14-3-3 and tau protein tested positive. Upon admission to our institution, the patient was found poorly responsive, responding almost exclusively to pain, unable to eat and in mild respiratory distress due to aspiration pneumonia. Patient presented also with an acute kidney injury, likely secondary to severe dehydration. Further work-up with brain magnetic resonance imaging (MRI) revealed restricted diffusion signal over the periventricular areas and over occipital lobes bilaterally, more prominent over the right (Figure 1) which are consistent with the typical "cortical ribbon sign" seen in almost more than 90% of sCJD patients; electroencephalography (EEG) showed disease-typical generalized periodic sharp wave complexes (GPSWC) at a frequency of 1 Hz, which typically occur in about 50% or two-thirds of the patients with sCJD (3) during the sub acute

*Infectious Disease Section, Internal Medicine Department, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico; †National Prion Disease Pathology Surveillance Center (NPDPSC), Case Western Reserve University, School of Medicine, Cleveland, OH; ‡PhD Program in Experimental Physiopathology and Neuroscience - Second University of Naples, Italy; §Neurology Department, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico; **Division of Neurology, Department of Clinical and Experimental Medicine, Second University of Naples, Italy; ††Neurology Section, HIMA Hospital, Caguas, Puerto Rico

The authors have no conflict of interest to disclose.

Address correspondence to: Jorge Bertrán-Pasarell, MD, FACP, Infectious Diseases Program, Department of Medicine, University of Puerto Rico Medical Sciences Campus, PO BOX 5067 San Juan PR 00936-5067. Email address: jbertranmd@hotmail.com